Determining when to start antiretroviral treatment (ART) is vitally important for people living with HIV. Yet the optimal point to start to maximise clinical benefit remains unknown. In the absence of randomised studies, current guidelines rely on conflicting observational data and expert opinion, and consequently diverge on this point. In the United States, ART is recommended irrespective of CD4 cell count. The World Health Organization now recommends starting ART at a CD4 cell count of 500 cells/µL, while the threshold for the United Kingdom and South Africa remains at 350 cells/µL.
The Strategic Timing of AntiRetroviral Treatment (START) study, one of the largest clinical trials on the treatment of HIV, will answer this question. START compares two treatment strategies: immediate treatment at a CD4 cell count of 500 cells/µL or higher versus deferring until the CD4 cell count decreases to 350 cells/µL or AIDS. START includes seven substudies, five of which will clarify the relative contribution of HIV and ART in common comorbidities. START is fully enrolled and expected to be completed in 2016. HIV advocates support the study’s design and have been involved from inception through enrolment. The trial will produce rigorous data on the benefits and risks of earlier treatment. It will inform policy and treatment advocacy globally, benefitting the health of HIV-positive people.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.